Delafloxacin is a fluoroquinolone lacking a basic substituent in position 7. It shows MICs remarkably low against Gram-positive organisms and anaerobes and similar to those of ciprofloxacin against Gram-negative bacteria. It remains active against most fluoroquinolone-resistant strains, except enterococci. Its potency is further increased in acidic environments (found in many infection sites). Delafloxacin is active on staphylococci growing intracellularly or in biofilms. It is currently evaluated as an intravenous and intravenous/oral stepdown therapy in Phase III trials for the treatment of complicated skin/skin structure infections. It was also granted as Qualified Infectious Disease Product for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, due to its high activity on pneumococci and atypical pathogens.
Introduction
In an era of increasing bacterial resistance, clinicians start facing situations in which therapeutic options become worryingly scarce. The so-called ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Enterobacter spp), pose specific problems as they escape the activity of most antibiotics [1] . Multidrug resistant strains in these species become highly prevalent in some regions like South-East Asia [2] and start to spread all over the world [3] . In this context, clinicians are forced to resort to old drugs for which resistance is still low because they were long neglected [4] . Yet, some of these molecules, like polymyxins, are toxic [5] . Moreover, most of them have been registered before modern pharmacokinetics/pharmacodynamics concepts were developed, so that optimal dosing is not established, making probably resistance development ineluctable [6] . Thus, finding new therapeutic options is urgently needed. A few novel molecules acting on still unexploited targets are now in preclinical or clinical development [7] but most successful efforts were oriented to the search of new molecules with optimized pharmacological profile in existing classes of drugs [8] [9] [10] .
Quinolones represent one of the few totally synthetic antibiotic classes. For this reason a lot of chemical modifications have been performed on the quinolone core in order to modulate their spectrum of activity, pharmacokinetic profile, or toxicity [11, 12] . Delafloxacin is one of the quinolones emerging from these studies. It is currently in phase III of clinical development for the treatment of complicated acute bacterial skin and skin structure infections. This review describes the pharmacological profile of this drug and summarizes the clinical data available so far.
History of delafloxacin
Delafloxacin (CAS registry number 189279-58-1) was described as WQ-3034 by Wakunaga Pharmaceutical Co., Ltd., Osaka & Hiroshima, Japan [13] . It was first licensed in 1999 to Abbott Park, IL and further developed as ABT-492. Its excellent activity was documented at that time against Staphylococcus aureus [14] , Streptococcus pneumoniae [14] [15] [16] , β-haemolytic streptococci [16] , some strains of Enterococcus faecalis and faecium [16] , Haemophilus influenzae [14, 16, 17] , Moraxella catarrhalis [14, 16] , Neisseria gonorrhoeae [16, 18] , Neisseria meningitidis [16] , Legionella spp [18] , Chlamydia pneumoniae [19] , mycoplasmas and ureaplasmas [20] , Helicobacter pylori [18] , enterobacteriaceae [14, 16] , Pseudomonas aeruginosa to some extent [16, 18] , Yersinia pestis [21] , anaerobes [14, 16] , and Mycobacterium tuberculosis including its intracellular forms [22] . Globally, it was considered as more potent against fluoroquinolone-susceptible or resistant Gram-positive organisms than other fluoroquinolones with a spectrum oriented towards Gram-positive organisms (trovafloxacin, moxifloxacin, gatifloxacin, and gemifloxacin) and as less potent against Gram-negative organisms than ciprofloxacin [23] . In 2006, the compound was licensed to Rib-X Pharmaceuticals Inc. (now Melinta Therapeutics, New Haven, CT), where it received the code name RX-3341.
Pharmacology of delafloxacin
Delafloxacin is a dual-targeting fluoroquinolone, capable of forming cleavable complexes with DNA and topoisomerase IV or DNA gyrase and of inhibiting the activity of these enzymes in both Gram-positive and Gram-negative bacteria [18] . In contrast to other molecules like ciprofloxacin, however, it shows a similar affinity for both types of enzymes [18] , which may explain its broad spectrum of activity. Intriguingly, delafloxacin is not a more potent inhibitor of topoisomerases than other fluoroquinolones [18] though it shows greater potency, especially against Gram-positive organisms. It has therefore been suggested that this improved activity was due to the conjunction of three unique features in this molecule, namely the presence of a heteroaromatic substituent at position 1, a weak polarity associated to the presence of a chlorine in position 8, and a lack of basic group in position 7 [24] . The absence of protonable substituent in position 7 gives to delafloxacin an anionic character at neutral pH, which is unusual for a fluoroquinolone. Figure 1 shows the ionization status of the molecule according the pH in comparison with that of moxifloxacin. At physiological pH (~ 7-7.4), delafloxacin is mainly found as an anion, but at slightly acidic pH (≤ 5.5), the majority form is uncharged, the calculated pKa of the carboxylic function being 5.6 (using Reaxys software; Elsevier, 2014). On the contrary, moxifloxacin is present mainly as a cation at pH lower than 5.5 and as a zwitterion at higher values. This specific characteristic may explain why delafloxacin accumulates much more in bacteria at acidic pH [25] , as the non-ionized form of a drug is considered as more diffusible though biological membranes. This feature therefore contributes to justify why delafloxacin potency is highly improved in acidic environments, in contrast with what is observed for other fluoroquinolones. For S. aureus, MICs decrease of up to 5-7 dilutions when measured at pH 5.5 vs. 7.4, reaching values as low as 0.00003 mg/L. On the same pH range, moxifloxacin MICs increase of 2-3 dilutions [25, 26] . For E. coli, K. pneumoniae, and P. aeruginosa, delafloxacin MICs are 4-6 dilutions lower at pH 5.5 than at pH 7.4, while those of ciprofloxacin are 3-8 dilutions higher [26, 27] .
Resistance to fluoroquinolones is primarily caused by target mutations, which occur in general in the primary target enzyme (thus more often in GyrA subunit of DNA gyrase in Gram-negative bacteria; ParC subunit of topoisomerase IV in Gram-positive bacteria, except S. pneumoniae [12, 28] ). Active efflux also contributes to decrease susceptibility, with narrow spectrum transporters expressed in Gram-positive pathogens and conferring resistance to fluoroquinolones only (like NorA, NorB, NorC, MdeA or the plasmid-encoded QacA and QacB [18, 23, 25, 37] . Although delafloxacin is affected by target modifications/mutations, its intrinsic activity is so much higher than that of other fluoroquinolones that the elevations in MICs are not as impactful. Delafloxacin is also claimed to be a poor substrate for efflux pumps from Gram-positive bacteria [37] and for the NorM efflux pump extruding fluoroquinolones out of N. gonorrheae [38] .
The capacity of delafloxacin to select resistance has been studied in MRSA in vitro [37] and was found infrequent (10 -9 to 10 -11 ). Moreover, concentrations preventing the selection of mutations (MPC [39] ) are low, ranging from 1 to 4 times the initial MIC, and globally 8-to 32-fold lower than for other quinolones. Preliminary data also confirm a low capacity of selecting resistance in N. gonorrheae, with MIC of the resistant isolates only 4 times higher than initial values [40] .
The equilibrated dual-targeting ability of delafloxacin may contribute to reduce resistance selection, as a mutation in each enzyme would be necessary to significantly affect susceptibility [37] .
Antibacterial activity
MIC distributions of delafloxacin are illustrated in Table 1 and Table 2 for a series of human pathogens, in comparison with those of marketed fluoroquinolones. Delafloxacin shows very low MIC against Gram-positive pathogens (Table 1) , with MIC being typically 2-4 fold lower than those of moxifloxacin, considered nowadays as the most potent anti-Gram-positive fluoroquinolone on the market [12] . At acidic pH, the difference in potency between the two antibiotics can even reach 7 dilutions [25] , as explained before. Noteworthy, delafloxacin MICs In these cases, activity is expected to be even higher in vivo, because of the acidic pH prevailing in the vagina [43] or in the stomach. This holds also true for E. coli or other enterobacteriaceae when involved in urine infection [27] . Globally, delafloxacin is as active (one dilution difference in MIC) as ciprofloxacin (considered as the most potent commercially available fluoroquinolone against Gram-negative bacteria [12] ) against enterobacteriaceae and P. aeruginosa. Importantly, it remains more active than ciprofloxacin against ciprofloxacin-resistant enterobacteriaceae. Delafloxacin is also remarkably active against anaerobes, including C. difficile.
Pharmacokinetics and pharmacodynamics
Pharmacokinetics of delafloxacin were first studied in healthy volunteers (Phase I trials). After intravenous administration of 300, 450 mg, 600, or 900 mg, Cmax values (reached after 1 h) were respectively 10, 16, 23, and 30 mg/L [44] . AUC were 24, 40, 59, and 92 mg.h/L, indicating that this parameter increased greater than proportionally in that range. More than 30% of the drug was excreted unchanged in urine within the first 12 hours after a single dose administration but metabolites have been detected, among which was a glucorono-conjugate [44, 45] . Protein binding was estimated at 16 % [46] . Half-life ranged from 8h after administration of 300 mg to 12 h after administration of higher doses. After oral administration of 450 mg [47] or 900 mg [48] , C max reached respectively 6 mg/L after 0.8 h and 10 mg/L after 1.38 h and AUC were 21 mg.h/L and 44 mg.h/L. In these conditions, an equivalence in total exposure is obtained when administering 300 mg intravenously or 450 mg orally [47] . C max was reduced by 20.5% and T max was delayed by 1.25 hours when administered under fed conditions but AUC was not affected [49] . The main pharmacokinetic data are presented for dosages used in clinical studies in Table   3 .
Additional pharmacokinetic studies were performed during Phase II trials. In Phase II patients treated for acute bacterial skin and skin structure infections by a daily dose of 300 mg intravenous BID (bis in die), C max were slightly lower (~ 7 mg/L) but AUC remained similar to that determined in healthy volunteers (21 mg.h/L [50] ). The dose should be reduced from 300 mg to 200 mg IV in case of severe renal insufficiency (eGFR < 30mL/min/1.73 m 2 ) [51] .
As other fluoroquinolones, delafloxacin is bactericidal in vitro [23, 25] . Its efficacy has been documented in a series of animal models treated by delafloxacin or another fluoroquinolone administered at the same dose. In renal abscesses by S. aureus it was more effective than moxifloxacin to reduce bacterial burden at doses of 10 or 30 mg/kg [52] . In granuloma pouch infection by Gram-negative bacteria, it was as effective as ciprofloxacin at doses of 25 or 50 mg/kg and reached higher concentration in the pouch despite lower plasma levels [53] .
Pharmacodynamic studies claim that the fAUC/MIC ratio (where fAUC is the AUC for the free drug) is the main driver of efficacy for fluoroquinolones [54] . This also hold true for delafloxacin based on recent animal data obtained in a model of S. aureus murine thigh infection, which showed that a 1 log decrease in inoculum can be reached for fAUC/MIC ratios ≤ 14.3 h [55] .
A target value for fAUC/MIC of 25-40 h is usually considered as acceptable for Gram-positive infections [54] . Considering that a free AUC of 18 mg.h/L can be reached after administration of 300 mg intravenously [50] , a pharmacodynamic susceptibility breakpoint of 0.5 mg/L could be proposed, which would cover most of the strains, including most fluoroquinolone-resistant Gram-positive bacteria except enterococci (see MIC 90 values in Table 1 ) and anaerobes. This is in accordance with Monte Carlo simulations, which concluded to a > 90 % target attainment rate for MICs ≤ 0.5 mg/L upon administration of both 300 and 450 mg BID [46] , rationalizing the doses that have been used in Phase III trials. At this stage however, PK/PD breakpoints for Gram-negative bacteria have not been determined.
Early studies using in vitro pharmacodynamic models also examined delafloxacin properties but neglected to consider the possible role of protein binding. They predicted that delafloxacin could achieve higher bacterial killing against S. aureus and S. pneumoniae and have a lower propensity to select for resistance than levofloxacin at simulated regimens mimicking AUC achievable in humans [56, 57] essentially because higher AUC/MIC ratios could be achieved with delafloxacin (12 times higher against S. aureus and 21-63 times higher for S. pneumoniae considering the specific strains used in these studies). Delafloxacin was also as effective as ciprofloxacin against E. coli at clinically-relevant simulated doses (400 mg delafloxacin vs. 500 mg twice daily ciprofloxacin, generating AUC/MIC ratios of 2200 and 1740 h, respectively) but required higher simulated doses (400 mg twice daily) to be at least as effective as ciprofloxacin against P. aeruginosa (AUC/MIC ratios of 280 and 120 h for delafloxacin and ciprofloxacin, respectively) [58] .
Activity of delafloxacin against persistent forms of infections
For specific bacterial species like staphylococci, the persistent character of infection has been attributed to their capacity to survive intracellularly [59] or to form biofilms [60] . Acting on these specific forms seems thus important in order to avoid recurrence of these infections. In in vitro models of intracellular infection by S. aureus [25] , delafloxacin proved as effective as moxifloxacin despite a lower cell accumulation level (2.5-fold vs. 7-fold for moxifloxacin). Yet, its activity was improved when cells are incubated at acidic pH (5.5), related to a 10-fold increase in its cellular accumulation level. Cell fractionation studies demonstrated that the bulk of the drug was located in the cytosol [25] , as observed for other fluoroquinolones [61, 62] , which suggests that the drug is able to freely cross biological membranes within the cells to gain access to the infected compartments. In in vitro models of biofilms, delafloxacin is also one of the most effective drugs among representatives of the main antistaphylococcal classes [63] , but its effect on biofilms formed by different clinical isolates depends on the local pH within the biofilm and on its capacity to diffuse within the structure [64] . Additional studies are needed however to determine whether these concepts also apply in vivo.
Clinical efficacy of delafloxacin
At this stage, two intravenous Phase II studies have been completed and two phase III trials are ongoing [10] . A first Phase II trial completed in 2008 (NCT00719810) compared delafloxacin (300 mg or 450 mg intravenously BID) to tigecycline (100 mg on day 1 then 50 mg intravenously BID) for the treatment of complicated acute bacterial skin and skin structure infections [65] .
Target infections were (a) wound infection having developed within 30 days of surgery, trauma, or an animal/insect bite injury, in patients having required purulent drainage from the wound or presenting at least three of the following symptoms: fever, swelling, erythema of ≥10 mm, pain, or tenderness; (b) abscess, without an open wound, having developed during the 7 days before enrollment, with purulent drainage or aspirate in patients showing evidence of a loculated fluid collection that required intervention within 48 h of enrollment and erythema and/or induration of ≥20 mm in diameter or tenderness; (c) cellulitis having developed during the 7 days before enrollment, with advancing edema, erythema, or induration; in patients showing documented fever or reported fever during the 3 days before enrollment, a white blood cell count of 10 × 10 9 /L or ≥10% band forms, or lymphangitis and adenopathy. Treatment duration was 5-14 days, based on the investigator's judgment. About 50 patients were enrolled in each arm, among whom more than 90 % completed the study (48, 51, 50 in the 300 and 450 mg delafloxacin and tigecycline arms, respectively for the mITT population); more than 70% were clinically evaluable and more than 50%, microbiologically evaluable. The mean duration of the treatment in the intent-to-treat population was 7.9 days, 7.5 days, and 6.8 days in the delafloxacin 300-mg, delafloxacin 450-mg, and tigecycline arms, respectively. S. aureus was isolated in 88% of patients having positive culture at baseline, among which two thirds were MRSA. Delafloxacin MIC in these strains ranged from ≤0.004 to 0.12 mg/L for both MSSA and MRSA. Cure rates at the test-of-cure visit in the clinically-evaluable population were higher than 90% in all arms with no statistical differences among them or between infection types. Cure rates were slightly higher with delafloxacin treatment for MRSA infections, but the difference did not reach significance.
Based on this Phase II study (see also next paragraph on safety), a dose of 300 mg IV was considered for further clinical trials.
A second Phase II trial completed in 2011 (NCT01283581) compared 5-14 days treatments of acute bacterial skin and skin structure infections with a minimum of 75 cm 2 erythema with delafloxacin (81 patients; 300mg intravenously BID), linezolid (77 patients; 600mg intravenously BID) or vancomycin (98 patients; 15mg/kg, up to 1250 mg, intravenously BID) [66, 67] . This study also concluded the equivalence of these treatments (72-78% success rate) when considering as endpoint the cessation of lesion spread and the absence of fever in the 48-72 h timeframe but better efficacy of delafloxacin when considering as endpoint a reduction >20% or >30% in lesion size after 48-72 hours. 
Safety profile
Fluoroquinolones present a large panel of adverse effects, some of which have been related to specific structural characteristics [12] . Yet, except for the halogen in position 8, which has been related to a risk of phototoxicity, the substituents present in delafloxacin are not found in other fluoroquinolones. No report has been published regarding the safety of the molecule in animal models and human data are limited to those collected in Phase II and ongoing phase III studies.
In the first Phase II study [65] , delafloxacin was well tolerated at a dose of 300 mg intravenously every 12 h. Adverse events were more frequent in patients receiving 450 mg BID, including gastrointestinal disorders and infusion-site pain. The treatment was discontinued in five patients because of adverse events (two in the delafloxacin 450-mg arm and three in the tigecycline arm) and eight serious adverse events were recorded (one in the delafloxacin 300-mg arm, three in the delafloxacin 450-mg arm, and four in the tigecycline arm) among which only a generalized seizure in a 53-year-old male in the delafloxacin 450-mg arm was considered as possibly related to the treatment. Globally, however, safety data available so far from Phase I and other Phase II studies did not reveal any specific adverse event [44, 68] , including on the cardiac function (no prolongation of QTc interval [69] ).
Conclusion
With its impressively low MICs against Gram-positive (especially MRSA) and anaerobic bacteria and reasonable activity against Gram-negative bacteria, delafloxacin may represent a breakthrough for the treatment of Gram-positive infections, especially when co-infections by other germs could be suspected. This is clearly the case for skin and soft tissues, where its clinical efficacy has already been demonstrated. Its other advantages in this context are its bactericidal character (as for other fluoroquinolones), its increased potency at the acidic pH of the skin and abscesses [43] , its low propensity of selecting resistance (with MPC close to the MIC), its availability as intravenous or oral formulations, its long half-life allowing twice-or oncea-day administration, and its activity on intracellular bacteria and on biofilms, which may play a role in these types of infections. The most promising other indication for this drug would be community-acquired bacterial pneumonia (taking advantage of its very high potency on pneumococci and on atypical pathogens) for which it was already granted as a Qualified Infectious Disease Product by the FDA. Its improved potency at acidic pH needs to be further exploited by exploring other specific indications for infections developing in acidic environments [43] and caused by susceptible bacteria like gastritis caused by H. pylori [18] . Its high activity on C. difficile infections may prevent the development of pseudomembranous colitis, as observed for other fluoroquinolones less active on anaerobes [70] . Further studies are needed to document its usefulness in these or other indications. Safety data are reassuring but still very preliminary, with Phase 3 studies ongoing. Thorough follow-up is needed as the occurrence of rare but serious side effects has been a reason for the abandon or withdrawal of many molecules within this class [10, 12] .
Executive summary (bullet points)
• Delafloxacin is a fluoroquinolone in phase III of clinical development showing the unusual property of lacking a basic substituent in position 7. This markedly improves its potency at acidic pH.
• Delafloxacin is highly potent on Gram-positive bacteria including MRSA and fluoroquinolone-resistant strains (except for enterococci), anaerobes, and, to a lesser extent, Gram-negative bacteria. Monte-Carlo simulations suggest that 0.5 mg/L could be a reasonable PK/PD breakpoint, which is well above the MIC of most target Grampositive organisms.
• Delafloxacin is administered twice (or once daily in specific situations) with equivalence in exposure obtained for 300 mg intravenously and 450 mg orally.
• Delafloxacin was as effective as tigecycline, vancomycin, or linezolid in Phase II trials of complicated skin and skin structures infections and is now studied in Phase III trials for the same indication (intravenously only or intravenously with shift to oral route after three days) as well as for uncomplicated gonorrhea (single oral dose). 
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